-+ 0.00%
-+ 0.00%
-+ 0.00%

Context Therapeutics Q3 net loss narrows 21% to $7.62 million

PUBT·11/10/2026 21:29:05
Listen to the news
Context Therapeutics Q3 net loss narrows 21% to $7.62 million
  • Context Therapeutics’ third-quarter 2026 net loss narrowed 21% year over year to $7.62 million.
  • Research and development expenses fell 34% year over year to $5.72 million.
  • Cash and cash equivalents totaled $34.41 million at September 30, 2026, with operations expected to be funded through early Q4 2027.
  • CTIM-76 weekly dosing achieved a 22% confirmed response rate and median progression-free survival of 5.6 months in evaluable platinum-resistant ovarian cancer patients.
  • Phase 1b dose expansion is expected in Q1 2027, with initial every-three-week dosing efficacy data due in Q2 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611101616PRIMZONEFULLFEED9874902) on November 10, 2026, and is solely responsible for the information contained therein.